https://www.yiliao.com/index.php?action=history&feed=atom&title=L2026M
L2026M - 版本历史
2026-04-17T21:47:37Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=L2026M&diff=315656&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-25T11:44:54Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>L2026M</strong> 是 <strong>[[ROS1]]</strong> 基因酪氨酸激酶结构域中的一种错义突变，具体为第 2026 位的<strong>亮氨酸</strong>（Leu）被<strong>甲硫氨酸</strong>（Met）取代。它是 ROS1 基因的“<strong>守门员突变</strong>”（Gatekeeper Mutation），约占 ROS1 阳性非小细胞肺癌获得性耐药病例的 7% 左右。该突变通过引入较大的侧链产生<strong>[[空间位阻]]</strong>，阻碍第一代 TKI <strong>[[克唑替尼]]</strong> 进入 ATP 结合口袋，从而导致耐药。然而，与位于溶剂前沿的顽固突变 <strong>[[G2032R]]</strong> 不同，L2026M 通常能够被下一代 TKI（如 <strong>[[瑞波替尼]]</strong>、<strong>[[他雷替尼]]</strong> 和 <strong>[[洛拉替尼]]</strong>）有效克服。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">L2026M</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">ROS1 Gatekeeper Mutation (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:ROS1_L2026M_structure_gatekeeper.png|100px|守门员位置的位阻效应]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">挡住老药，放进新药</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">涉及基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[ROS1]]</strong> (Kinase Domain)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">氨基酸改变</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">Leu2026 → Met</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">ALK 对应位点</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[L1196M]]</strong> (完全同源)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">功能分类</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[守门员突变]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">耐药药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[克唑替尼]]</strong>, [[恩曲替尼]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">敏感药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[瑞波替尼]]</strong>, <strong>[[他雷替尼]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">相似位点</th><br />
<td style="padding: 6px 12px; color: #0f172a;">EGFR <strong>[[T790M]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：守门员的叛变</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
L2026 位于 ROS1 激酶结构域 ATP 结合口袋的深处，被称为“守门员”位置（Gatekeeper position），它控制着抑制剂能否进入疏水后袋。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>野生型 (L2026)：</strong> 侧链较小的<strong>亮氨酸</strong>（Leu）允许克唑替尼等 I 型抑制剂顺利结合。</li><br />
<li style="margin-bottom: 12px;"><strong>突变型 (L2026M)：</strong> 突变为<strong>甲硫氨酸</strong>（Met）后，侧链体积变大且更长。这个凸出的侧链像一个门栓，直接在物理空间上把克唑替尼“顶”了出来，导致亲和力下降数百倍。</li><br />
<li style="margin-bottom: 12px;"><strong>新药的对策：</strong> 新一代 ROS1 抑制剂（如瑞波替尼）通常分子结构更加紧凑（大环结构）或结合模式更灵活，能够巧妙地绕过这个甲硫氨酸侧链，因此仍能保持极高的抑制活性（IC50 < 1 nM）。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床策略：换代即由生</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">相比 G2032R，它是“温和”的敌人</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
L2026M 属于那种“纸老虎”式的耐药突变。虽然它让一代药失效，但只要及时更换下一代药物，患者通常能获得较长的生存获益。这与令洛拉替尼也束手无策的 <strong>[[G2032R]]</strong> 形成鲜明对比。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #eff6ff; border-bottom: 2px solid #60a5fa; color: #1e40af;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 25%;">药物</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 20%;">类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 55%;">对 L2026M 的疗效</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b91c1c;"><strong>[[克唑替尼]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">第一代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;"><br />
<strong>耐药</strong>。L2026M 是其主要耐药机制之一。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #166534;"><strong>[[瑞波替尼]]</strong><br>(Repotrectinib)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">下一代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;"><br />
<strong>高度敏感</strong>。TRIDENT-1 研究显示其对守门员突变有强效抑制，ORR 极高。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #166534;"><strong>[[他雷替尼]]</strong><br>(Taletrectinib)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">下一代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;"><br />
<strong>高度敏感</strong>。TRUST-I 研究证实其能克服 L2026M 耐药。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #166534;"><strong>[[洛拉替尼]]</strong><br>(Lorlatinib)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">第三代</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;"><br />
<strong>敏感</strong>。尽管对 G2032R 效果不佳，但洛拉替尼对 L2026M 非常有效。<br />
</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Gainor JF, et al. (2017).</strong> <em>Molecular mechanisms of resistance to crizotinib in ROS1-positive lung cancer.</em> <strong>[[JCO Precision Oncology]]</strong>.<br><br />
<span style="color: #475569;">[机制解析]：通过对耐药样本的深度测序，确认 L2026M 是仅次于 G2032R 的常见耐药位点，并明确了其空间位阻机制。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Drilon A, et al. (2024).</strong> <em>Repotrectinib in ROS1-Fusion-Positive Non-Small-Cell Lung Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[治疗突破]：TRIDENT-1 研究。证实了瑞波替尼作为新一代 TKI，能够广泛覆盖包括 L2026M 和 G2032R 在内的多种耐药突变。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Davare MA, et al. (2015).</strong> <em>Structural insight into selectivity and resistance profiles of ROS1 inhibitors.</em> <strong>[[PNAS]]</strong>.<br><br />
<span style="color: #475569;">[结构生物学]：详细比较了 ROS1 与 ALK 的结构同源性，预测了 L2026M 与 ALK L1196M 具有相似的耐药特征。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
L2026M · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">ALK 对应</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[L1196M]]</strong> (同源守门员)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">对比突变</td><br />
<td style="padding: 10px 15px; color: #334155;">vs <strong>[[G2032R]]</strong> (更难治) • vs <strong>[[S1986Y]]</strong> (构象突变)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">一代药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克唑替尼]] (耐药) • [[恩曲替尼]] (耐药)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">特效药物</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[瑞波替尼]]</strong> • [[他雷替尼]] • [[洛拉替尼]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020